ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
Biological Pathways Linking Metabolic Disease and Cancer Mechanistic research suggests that obesity and T2D often lead to a state of chronic, low-grade inflammation and, crucially, sustained hyperinsulinemia (excessively high insulin levels)
At MTC, the goal isn't just prescribing a pill
In the T2D group, 17 NAION events were recorded in patients on semaglutide compared to 6 events in the non0GLP-1 RA group
It cites an email with the subject line This might be the easiest way to start Ozempic sent from a nonsensical .us email address, [email protected], with an email that routes to a MEDVi landing page with tracking parameters
GPR120/FFAR4: A potential new therapeutic target for inflammatory bowel disease
